دورية أكاديمية
أعرض في EDS

COVID-19 Booster Vaccine Equity for Patients With Cancer

التفاصيل البيبلوغرافية
العنوان: COVID-19 Booster Vaccine Equity for Patients With Cancer
المؤلفون: Rahul N. Prasad, MD, MBA, Manali Patel, MD, MPH, MS, Joshua D. Palmer, MD
المصدر: Advances in Radiation Oncology, Vol 7, Iss 5, Pp 100939- (2022)
بيانات النشر: Elsevier, 2022.
سنة النشر: 2022
المجموعة: LCC:Medical physics. Medical radiology. Nuclear medicine
LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
مصطلحات موضوعية: Medical physics. Medical radiology. Nuclear medicine, R895-920, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
الوصف: COVID-19 has caused greater than 300 million documented infections worldwide including over 5 million confirmed deaths. Patients with cancer are particularly vulnerable due to a combination of disease and therapy-related effects. Available vaccines were highly effective against the original viral strains in clinical trials. However, initial vaccination efforts in this vulnerable population were impacted by federal policy that created substantial vaccine scarcity and allocation difficulties by recommending prioritization of unmanageably large patient populations including the entire elderly population and patients over the age of 16 with broadly defined, high-risk medical conditions (including cancer). We found that these overly broad recommendations led nearly two-thirds of states to elect not to give adequate vaccination priority to patients with cancer, exposing this vulnerable population to potentially preventable infection. With the virulent omicron variant spreading rapidly, there is newfound concern about waning immunity, particularly in immunocompromised populations. To address this issue, the Centers for Disease Control is recommending boosters for patients who meet age, occupational exposure, or medical criteria, in similar fashion to recommendations during the initial vaccination phase. Thus, this approach raises the question of whether state-level decisions on how to sub prioritize may inadvertently once again result in delayed immunizations for particularly vulnerable subgroups – such as patients with cancer. We discuss the implications of this public health policy on the likelihood of timely re-vaccination of patients with cancer. With the omicron variant continuing its unchecked global spread, equitable distribution of booster immunizations is critical to minimizing inherent medical and socioeconomic inequities in COVID-related morbidity and mortality.
نوع الوثيقة: article
وصف الملف: electronic resource
اللغة: English
تدمد: 2452-1094
Relation: http://www.sciencedirect.com/science/article/pii/S245210942200046X; https://doaj.org/toc/2452-1094
DOI: 10.1016/j.adro.2022.100939
URL الوصول: https://doaj.org/article/22ee923f476a484eba0b7414d634e2cf
رقم الأكسشن: edsdoj.22ee923f476a484eba0b7414d634e2cf
قاعدة البيانات: Directory of Open Access Journals
الوصف
تدمد:24521094
DOI:10.1016/j.adro.2022.100939